William Blair Equities Analysts Raise Earnings Estimates for Amedisys, Inc. (NASDAQ:AMED)

Amedisys, Inc. (NASDAQ:AMEDFree Report) – Equities research analysts at William Blair boosted their Q3 2024 EPS estimates for Amedisys in a report released on Thursday, July 25th. William Blair analyst M. Larew now anticipates that the health services provider will earn $1.15 per share for the quarter, up from their previous forecast of $1.12. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Amedisys’ current full-year earnings is $4.57 per share. William Blair also issued estimates for Amedisys’ Q4 2024 earnings at $1.23 EPS and FY2024 earnings at $4.72 EPS.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $101.00 target price on shares of Amedisys in a research report on Thursday. StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $100.67.

View Our Latest Report on AMED

Amedisys Stock Up 0.2 %

Shares of AMED opened at $97.75 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.09 and a quick ratio of 1.09. Amedisys has a 1-year low of $89.55 and a 1-year high of $98.46. The firm has a fifty day moving average price of $94.81 and a 200 day moving average price of $93.79.

Amedisys (NASDAQ:AMEDGet Free Report) last posted its earnings results on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Amedisys had a net margin of 4.02% and a return on equity of 12.56%. The firm had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. During the same period last year, the firm posted $1.00 EPS. The company’s revenue was up 2.7% on a year-over-year basis.

Institutional Investors Weigh In On Amedisys

Several hedge funds have recently made changes to their positions in the business. Retirement Systems of Alabama raised its stake in Amedisys by 0.3% during the 4th quarter. Retirement Systems of Alabama now owns 40,871 shares of the health services provider’s stock valued at $3,885,000 after acquiring an additional 125 shares during the last quarter. Treasurer of the State of North Carolina increased its holdings in shares of Amedisys by 1.0% in the fourth quarter. Treasurer of the State of North Carolina now owns 14,204 shares of the health services provider’s stock valued at $1,350,000 after purchasing an additional 140 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Amedisys by 2.2% during the first quarter. Louisiana State Employees Retirement System now owns 9,400 shares of the health services provider’s stock worth $866,000 after purchasing an additional 200 shares during the last quarter. Bridge City Capital LLC lifted its holdings in shares of Amedisys by 0.8% during the first quarter. Bridge City Capital LLC now owns 29,861 shares of the health services provider’s stock worth $2,752,000 after purchasing an additional 231 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Amedisys by 0.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,199 shares of the health services provider’s stock valued at $2,876,000 after buying an additional 255 shares during the last quarter. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Company Profile

(Get Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.